ArriVent collapses on disappointing lung cancer data
More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.